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Walking testEnzyme replacement therapy inmucopolysaccharidosis type II (MPS
II, Hunter disease) is extremely expensive and treatment effects are
hardly predictable due to phenotypic variability [1]. We would like to
address an additional problem — the paucity of robust clinical tests
allowing for monitoring of effectiveness of enzymatic treatment.
Since 2009 enzyme replacement therapy with idursulfase has been
offered to all Polish patients with MPS II aged N5 years, independently
on disease severity. A total of 40 patients have started treatment up to
date. In 26 persons treatment was eventually discontinued due to dis-
ease progression, death of the patient (two cases), or anaphylaxis
(two cases). Unfortunately, reaching the consensus on treatment failure
required sometimes several years of observation, as the classic clinical
monitoring parameters [2,3] were not always informative. Specifically:
the distance covered in the six-minutewalking test could not be applied
in 20 non-ambulant patients, pulmonary function testswere performed
only in older patients without intellectual disability and monitoring of
liver size or of heart involvement was helpful only in those patients
with significant hepatomegaly or cardiac dysfunction.
Surprisingly, basic anthropometric measurements proved to be very
useful for assessment of treatment effectiveness in some doubtful cases.
Noweight gain or evenweight loss was observed in severely affected pa-
tients, contrary to those withmilder disease in whom an overall anabolic
effect was observed (Fig. 1). Our findings are consistent with previously
published observations [4,5] reporting decline of the linear growth in un-
treated children withMPS II, which started at the age of four to six years.
In conclusion, we recommend thoughtful use of growth charts, as it
can help to avoid wasting millions for prolonged enzymatic therapy in
some cases of MPS II.http://dx.doi.org/10.1016/j.ymgmr.2015.12.002
2214-4269/© 2015 The Authors. Published by Elsevier Inc. This is an open access article underContributors' statements
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Fig. 1. Body weight and growth changes in studied patients with MPS II. A single female patient was marked with a dotted line. (CDC growth charts for boys; developed by the National
Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion, 2000).
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Fig. 1 (continued).
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